Novel targets in pain research: The case for CB2 receptors as a biorational pain target

Current Anaesthesia and Critical Care

Volumn 20, Issue 5-6, 2009, Pages 198-203

  Brownjohn, Philip W ^a   Ashton, John C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoid; CB2 receptor; Chronic pain; Endocannabinoid; Neuropathic pain; Psychoactivity

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; A 796260; A 836339; AM 1221; AM 1710; AM 1714; AM 724; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABIS; CARBAMAZEPINE; DRONABINOL; GABAPENTIN; GW 405833; JWH 142; JWH 143; LIDOCAINE; MDA 7; NARCOTIC ANALGESIC AGENT; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTICLE; ATAXIA; CLINICAL TRIAL; CONFUSION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG PENETRATION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HYPERALGESIA; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT;

EID: 69649090362     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2009.07.014     Document Type: Article

References (40)

1. Vissers K.C. The clinical challenge of chronic neuropathic pain. Disabil Rehabil 28 6 (2006) 343-349
2. Torrance N., et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 7 4 (2006) 281-289
3. Finnerup N.B., et al. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 9 2 (2007) 36
4. Dworkin R.H., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60 11 (2003) 1524-1534
5. Iskedjian M., et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23 1 (2007) 17-24
6. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 66 2-3 (2002) 123-142
7. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 6441 (1993) 61-65
8. Ashton J.C., and Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 5 2 (2007) 73-80
9. Huang S.M., et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99 12 (2002) 8400-8405
10. Valenzano K.J., et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 5 (2005) 658-672
11. Viscomi M.T., et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3 K/Akt pathway. J Neurosci 29 14 (2009) 4564-4570
12. Galiegue S., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232 1 (1995) 54-61
13. Ibrahim M.M., et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100 18 (2003) 10529-10533
14. Van Sickle M.D., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 5746 (2005) 329-332
15. Suarez J., et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509 4 (2008) 400-421
16. Khanolkar A, Lu D, Makriyannis A.W.O. Patent 99/57107; 2001.
17. Ashton J.C., et al. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem 15 14 (2008) 1428-1443
18. Raduner S., et al. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 281 20 (2006) 14192-14206
19. Wotherspoon G., et al. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 1 (2005) 235-245
20. Racz I., et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28 46 (2008) 12125-12135
21. Zhang J., et al. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 27 45 (2007) 12396-12406
22. Jordt S.E., et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427 6971 (2004) 260-265
23. Akopian A.N., et al. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 28 5 (2008) 1064-1075
24. Akopian A.N., et al. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 30 2 (2009) 79-84
25. Cortright D.N., Krause J.E., and Broom D.C. TRP channels and pain. Biochim Biophys Acta 1772 8 (2007) 978-988
26. Suzuki R., and Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. Neurosignals 14 4 (2005) 175-181
27. PharmosCorporation. CB2-selective program: Cannabinor, ; 2009 [25 April 2009].
28. GlaxoSmithKline. A study of the effects of CB2 compound of GW842166 in patients with osteoarthritis, ; 2009 [cited 2009 25 April 2009].
29. Yao B.B., et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153 2 (2008) 390-401
30. Yao B.B., et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328 1 (2009) 141-151
31. Beltramo M., et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23 6 (2006) 1530-1538
32. Ibrahim M.M., et al. CB2 cannabinoid receptor mediation of antinociception. Pain 122 1-2 (2006) 36-42
33. Rahn E.J., Makriyannis A., and Hohmann A.G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152 5 (2007) 765-777
34. Rahn E.J., et al. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 327 2 (2008) 584-591
35. Guerrero A.V., et al. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett 433 2 (2008) 77-81
36. Naguib M., et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 155 7 (2008) 1104-1116
37. Yamamoto W., Mikami T., and Iwamura H. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583 1 (2008) 56-61
38. Whiteside G.T., et al. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 528 1-3 (2005) 65-72
39. Leichsenring A., et al. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol 379 6 (2009) 627-636
40. Hu B., et al. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 143 3 (2009) 206-212